Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5-year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or nabpaclitaxel and gemcitabine showing the largest clinical benefits. Newer genomic classifications of PDAC may provide a rationale for targeted therapies or immunotherapies, although at present these remain largely experimental. This review discusses the evidence behind the currently used regimens, while introducing the potential future of pancreatic cancer care.
Introduction
Although metastatic pancreatic ductal adenocarcinoma (mPDAC) has a low incidence of 4.2 per 100 000 globally, 1 it is projected to become the second highest cause of cancer death by 2020 in the United States. 2 Systemic treatments are the mainstay of mPDAC management. These primarily consist of cytotoxic chemotherapy, although targeted treatments, such as the tyrosine kinase inhibitor erlotinib, have been used with limited benefit. 3 A major research development has been full sequencing of the whole genome of a representative sample of patients with pancreas cancer first being published in 2015 . 4 This has demonstrated several different subtypes and previously uncharacterised driver pathways, allowing more tailored design of trials, with treatments developed around rational targets.
This review will summarise the current standards of diagnosis and care for mPDAC treated with systemic therapy, as well as recent advances that have led to changes in practice. Finally, the potential future directions of care will be discussed, including genetic driver mutations and their implications for clinical trials.
Clinical presentation
The majority of patients with pancreatic cancer have metastases at diagnosis. Many patients will have nonspecific constitutional symptoms prior to diagnosis, such as anorexia, weakness, fatigue and weight loss. The insidious and non-specific nature of these can lead to a delayed diagnosis, a common feature of this disease. New-onset hyperglycaemia or diabetes has been recognised as a potential harbinger of occult mPDAC. There is emerging evidence that ultrasound of the pancreas gland to screen for pancreas cancer may be justified in new onset diabetes in the absence of other risk factors, or sudden deterioration in glycaemic control in the known diabetic.
Symptoms of the primary malignancy, if present, usually relate to mass effect, but can manifest as disrupted endocrine or exocrine function. Patients with lesions in the head of the pancreas may present with jaundice due to biliary obstruction. In this case the jaundice can often be relieved by the insertion of a biliary stent through endoscopic retrograde cholangio-pancreatography.
Diagnosis and prognosis
The gold standard for the diagnosis of mPDAC is a biopsy. This may be obtained percutaneously with radiological guidance or through endoscopic ultrasoundguided fine needle aspiration (EUS-FNA).
Dedicated pancreatic computed tomography (CT) or magnetic resonance imaging (MRI) scans are essential in locally advanced or early disease, for assessment of resectability. Prior to surgery a CT of the chest, abdomen and pelvis is necessary to exclude metastatic disease.
However, the priority of imaging in established mPDAC is to gauge the burden of metastatic disease and to act as a baseline measure prior to any systemic therapy.
The carbohydrate antigen (CA) 19-9 is the most frequently elevated tumour marker in mPDAC. The low positive predictive value of CA 19-9 means it has no current role in screening, but for patients with confirmed mPDAC its level prior to treatment is an independent prognostic factor for survival. 5 It can be used as a monitoring tool during treatment in patients in whom it is expressed, but it must be recognised that a high false negative rate exists for patients who are Lewis blood type negative (Le a-b− ). 6 The 5-year survival of all stages of pancreatic cancer is around 8%, with mPDAC being even lower. 7 The median overall survival (OS) for mPDAC is generally reported between 3 and 11 months, with around 10% of patients living beyond 2 years with upfront modern combination chemotherapy, the current standard of care. 8 
Chemotherapy
Physical frailty can be a barrier to administering systemic treatments, and can affect the generalisability of the results of the larger clinical trials which usually only include good performance status patients. This is defined as either a Karnofsky Performance Score (KPS) of ≥70 or an Eastern Cooperative Oncology Group (ECOG) score of 0-1. Clinical judgement is consequently imperative when deciding on specific regimens.
First-line treatment: good performance status
Patients with a good performance status are generally suitable for combination chemotherapy. The current choices are combination fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or gemcitabine with nab-paclitaxel. Taking into account that FOLFIRI-NOX produced a better OS than gemcitabine with nabpaclitaxel; it is the preferred option in the very fit and young or in those where downstaging is the aim of therapy.
Fluorouracil, folinic acid, irinotecan and oxaliplatin
The pivotal study establishing the benefit of this regimen in mPDAC was conducted by Conroy et al. in 2011 (Table 1) . 9 This Phase II-III trial randomised 342 patients to either FOLFIRINOX or single-agent gemcitabine at a 1:1 ratio. All patients had an ECOG score ≤1.
Patients in the FOLFIRINOX group had a median OS of 11.1 months compared to 6.8 months for those on gemcitabine (hazard ratio (HR) = 0.57, 95% confidence interval (CI) 0.45-0.73; P < 0.001). The objective response rate (ORR) was also higher; 31.6% for FOLFIR-INOX against 9.4% for gemcitabine (P < 0.001).
FOLFIRINOX is more toxic than gemcitabine, with higher rates of neutropenia, febrile neutropenia, thrombocytopenia, diarrhoea, sensory neuropathy and liver enzyme derangement reported in the Conroy study. 9 It requires central venous access due to a 46-h infusion of fluorouracil. Regardless, its use is associated with a longer maintained quality of life (QoL). In an assessment of the Conroy cohort, QoL impairment was delayed for FOLFIRINOX compared to gemcitabine. It is routine for medical oncologists to monitor toxicity and alter doses to tailor the chemotherapy to the patient's needs. For example it is possible to dose reduce oxaliplatin to limit nerve toxicity.
Gemcitabine and nanoparticle albumin-bound paclitaxel
In 2013, the benefit of gemcitabine in combination with the taxane nanoparticle albumin-bound paclitaxel (gem/nab-pacli) was demonstrated in the MPACT trial by Von Hoff et al. (Table 1) . 10 This study compared gem/-nab-pacli to gemcitabine alone in 861 patients on a 1:1 ratio. Participants had a KPS ≥ 70%, allowing some patients to be enrolled who would not otherwise be suitable for FOLFIRINOX.
The median OS was 8.5 months for gem/nab-pacli compared to 6.7 months for gemcitabine (HR = 0.72, 95% CI 0.62-0.83; P < 0.001). The combination group had a significantly higher rate of peripheral neuropathy, neutropenia and fatigue. No QoL measures were reported. Although biomarker studies have been performed, with SPARC the main candidate, as yet there is no established predictive biomarker for the use of this regimen. Other gemcitabine-based regimens There are other gemcitabine-based regimens commonly used for good performance status patients in the first line. There is evidence to support the combination of gemcitabine and a fluoropyrimidine, the most common being either capecitabine or fluorouracil.
Gemcitabine may also be combined with a platinum agent, either cisplatin (most commonly) or oxaliplatin. Against gemcitabine alone, there is limited evidence that this combination may confer a small survival benefit from several trials. [13] [14] [15] [16] A greater benefit for platinumcombined therapy may potentially be conferred for patients with known BRCA1/2 or other hereditary DNA repair mutations, or those with highly rearranged genomes. 4, 17 Despite extensive research, the only positive trial of a targeted agent in mPDAC was performed by Moore et al., in which gemcitabine in combination with erlotinib showed a statistically significant survival benefit against gemcitabine alone (HR = 0.82, 95% CI 0.69-0.99; P = 0.038), with a median OS of 6.24 months versus 5.91 months and 1 year survivals of 23% versus 17%. 3 Given the small clinical benefit and the high cost of the drug, this combination is not commonly used in clinical practice. The high rate of Kirsten rat sarcoma virus (K-RAS) gene mutation (93%) in pancreas cancer may explain why this targeted agent had such a small benefit in all comers. We await results of biomarker selection studies of this agent in the rare RAS wildtype subgroup.
Single-agent gemcitabine is still an option for patients, as first demonstrated by Burris et al. in 1997 using fluorouracil as a comparator (Table 1) . 11 That trial showed a clinically beneficial response rate of 23.8% for gemcitabine compared to 4.8% for fluorouracil. The median OS was 5.65 months versus 4.41 months (P = 0.0025) for gemcitabine and fluorouracil respectively, while at 12 months, 18% of gemcitabine patients and 2% of fluorouracil patients were still alive. Gemcitabine may be used when other comorbidities preclude the use of either oxaliplatin or a taxane. Its favourable toxicity profile may also be preferred by many patients.
First-line treatment: poor performance status
Patients with a poor performance status should receive either single-agent chemotherapy or best-supportive care. Almost all patients, regardless of their administered treatment, should be referred to a specialist palliative care service as a priority. 18 Single-agent gemcitabine has been shown to relieve symptoms directly, making it useful as a palliative measure when toxicity is a concern.
11 Gemcitabine additionally has a small survival advantage against fluorouracil, making it a preferred drug over fluoropyrimidines, although these are also an option.
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Second-and third-line treatment
There is increasing evidence to support specific chemotherapy regimens in the second-line. OS with BSC alone has been shown to be around 2 months. 19 A previous meta-analysis of primarily early-phase trials demonstrated that the use of second-line treatment is associated with improved survival compared to supportive care alone, with several ongoing clinical trials. 20 In general, clinical treatment decisions are guided by a patient's ongoing performance status and their previously administered regimens.
Previous gemcitabine
Nanoliposomal irinotecan-based regimens
For patients who have previously received gemcitabinebased regimens, the best level of evidence is for fluorouracil in combination with folinic acid and nanoliposomal irinotecan (nal-iri/FU/FA). 12 This regimen was assessed in the NAPOLI-1 Phase III trial published in 2016 ( Table 1 ). The combination arm of nal-iri/FU/FA had a modest survival benefit over fluorouracil and folinic acid (mOS 6.1 months vs 4.1 months, HR = 0.67, 95% CI 0.49-0.92; P = 0.012). No significant difference was shown between the fluorouracil and folinic acid arm and nanoliposomal irinotecan monotherapy. The combination group had more diarrhoea, neutropenia, vomiting and fatigue than either of the monotherapy arms, but overall QoL was reportedly not worsened. As this agent is not yet reimbursed in Australia, its use is somewhat limited.
Combination chemotherapies
An alternative regimen for patients who have previously received gemcitabine-based treatment with a very good performance status (ECOG 0-1) is FOLFIRINOX. This is supported by international guidelines and several retrospective reviews, but has not undergone prospective analysis. [21] [22] [23] The toxicity of prior regimens also has to be taken into account when choosing a second line option, for example, both nab-paclitaxel and oxaliplatin cause peripheral neuropathy and this may limit using these drugs sequentially.
FOLFOX was shown in the CONKO-003 Phase III trial to have a survival benefit for patients who had previously received gemcitabine-monotherapy, published in 2014.
While the FOLFOX group had a survival advantage (mOS 5.9 months vs 3.3 months, HR = 0.66, 95% CI 0.48-0.91; P = 0.010) and progression-free survival benefit (PFS 2.9 months vs 2.0 months, HR = 0.68, 95% CI 0.50-0.94; P = 0.019), these data have limited value for two reasons: first, patients were recruited in the era before nab-paclitaxel was a standard addition to first-line gemcitabine, and second, the analysed group included both those with locally advanced and metastatic disease.
The CONKO-003 trial was subsequently followed by the PANCREOX trial, published in 2016. 25 In PAN-CREOX, 108 patients with gemcitabine-resistant locally advanced or mPDAC were randomised to either FOL-FOX or fluorouracil. In contrast to CONKO-003, survival was inferior in the FOLFOX group (mOS 6.1 months vs 9.9 months, HR = 1.78, 95% CI 1.08-2.93), P = 0.024), with a higher rate of grade 3/4 adverse events (63% vs 11%). Accordingly, FOLFOX (or CAPOX) remains only a category 2A recommendation in international guidelines, such as the United States National Comprehensive Cancer Network (NCCN). 21 For patients of poorer performance status, single-agent fluoropyrimidines, either fluorouracil or capecitabine, are options and endorsed by international guidelines. 21 
Previous fluorouracil
For patients who have previously received a fluorouracilbased therapy, such as FOLFIRINOX, it is reasonable to consider the use of gem/nab-pacli, assuming a maintained KPS ≥70, as recommended by the current NCCN guidelines. 21 However, in Australia, second-line gem/nab-pacli is not approved by the PBS if the patient has previously received PBS-subsidised therapy. 1 In the NAPOLI-1 study, between 42% and 46% of participants had received previous fluorouracil-based therapy, depending on the enrolled arm, and between 10% and 14% of patients had received previous irinotecan-based treatment. This suggests that nal-iri may be a useful agent in patients with prior 5FU based chemotherapy.
For any patient who has maintained a good performance status after progressing on first-line treatment, enrolment in a clinical trial should be encouraged. 21 
Newer treatments under trial
Numerous trials are underway for mPDAC interventions. A summary of studies actively recruiting patients in Australia and New Zealand, excluding non-specific basket trials, is shown in Table 2 . Searching the clinicaltrials. gov database produces 50 actively recruiting studies worldwide across all phases specific for mPDAC, and 16 others that may recruit mPDAC patients based on molecular characteristics. Many of these involve the following mechanisms:
Immune checkpoint inhibitors
Immune checkpoints are regulatory molecules expressed on T cells to augment their response when presented with tumour peptide antigens. 26 They may act to enhance or suppress the interaction between a T-cell receptor (TCR) and the major histocompatibility complex (MHC) of an antigen-presenting cell (APC). They consequently are potential targets for anti-cancer immunotherapy.
The main sites of investigation have so far been the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) receptor and the programmed cell death protein 1 (PD-1) TCR and its associated APC ligand (PD-L1). Inhibition of these sites acts to stimulate the immune system.
Cytotoxic T-lymphocyte-associated protein 4
The first Phase II trial of ipilimumab, an IgG1 monoclonal antibody (mAb) CTLA-4 antagonist, in mPDAC was published in 2010 with 27 participants. 27 Disappointingly, there were no objective responders by RECIST criteria, although one participant did have delayed tumour regression.
A subsequent Phase Ib trial of ipilimumab with or without a granulocyte macrophage colony-stimulating factor (GM-CSF) vaccine (GVAX) showed more benefit with a higher dose of ipilimumab. When given as monotherapy, two patients out of 15 showed stable disease for 7 and 22 weeks respectively, while in the combination group three patients out of 15 had prolonged disease stability for 31, 71 and 81 weeks. 28 Tremelimumab, an IgG2 mAb with the same mechanism of action as ipilimumab, has also been investigated in mPDAC. A Phase Ib trial used this medication in combination with gemcitabine as first-line treatment for mPDAC patients. 29 The study drug was given to 34 patients in total, with two partial responses documented for patients in the arm with the highest dose given (n = 2/19).
Several ongoing studies are investigating the role of CTLA-4 antagonists in mPDAC, including both 
PD-1 and PD-L1
There is scant evidence to support the routine clinical use of either PD-1 or PD-L1 inhibitors in mPDAC outside of a clinical trial. In a Phase I basket trial of a PD-L1 inhibitor, there were no responses in any of the 14 patients enrolled with mPDAC. 30 However, there are several early-phase studies underway investigating the potential role of pembrolizumab, nivolumab (both anti-PD-1) and durvalumab (anti-PD-L1), either as singleagents or in combination with chemotherapy or GVAX. 31 It is hypothesised that the observed low response to immunotherapy may be in part related to the immunosuppressive milieu of pancreatic cancer. 32 This is despite the fact PD-L1 expression is often elevated in mPDAC, 33 a factor in other malignancies associated with an increased likelihood of response to its inhibition. 34 Preclinical studies suggest this may be related to transforming growth factor-β (TGFβ) production, providing a novel pathway for co-inhibition with immune checkpoint inhibitors. 32 There is also evidence that PD-1 inhibition is useful in the small minority of mPDACs with high microsatellite inhibition (MSI-H). In the Keynote-158 trial using pembrolizumab, an ORR of 50% was observed for all patients; at the time of the report, only four participants with MSI-H mPDAC had been enrolled. 35 The United States Food and Drug Administration (FDA) data show that six total MSI-H mPDAC patients have received pembrolizumab with reported outcomes, with an ORR of 83%. 36 Any progressive MSI-H cancer is now an approved indication for pembrolizumab by the FDA, although this is contingent on later confirmatory trials. 36 However, the estimated prevalence of MSI-H in sporadic mPDAC is <1%. 37 
PARP-inhibitors
Recent analyses of the pancreatic cancer genome revealed a significant burden of BRCA1, BRCA2 and CDK, cyclin-dependent kinase; CSF1, macrophage colony-stimulating factor-1; FOLFOX, fluorouracil, folinic acid and oxaliplatin; FU/FA, fluorouracil and folinic acid; gBRCA, germline BRCA-mutation; Gem/nab-pacli, gemcitabine and nanoparticle albumin-bound paclitaxel; IL-10, interleukin-10; mCRC, metastatic colorectal cancer; MEK, mitogen-activated protein kinase; mNSCLC, metastatic non-small cell lung cancer; Nal-IRI, nanoliposomal irinotecan; PARP, poly(ADP-ribose) polymerase; PD1, programmed cell death protein-1.
PALB2-gene mutations, present in 10% of malignancies sequenced. 4 This provides a logical mechanism for both response to platinum chemotherapy and, in the context of clinical trials, the use of poly(ADP-ribose) polymerase (PARP) inhibitors, such as olaparib.
In a recent Phase II trial of olaparib in patients with known germline mutations in BRCA1 or BRCA2, 23 participants with advanced pancreatic cancer received this treatment. 38 Within this group, the tumour response rate was 22%, providing a promising area of further investigation. Accordingly, the Phase III POLO trial for this patient group is underway, assessing olaparib 'switch maintenance' against placebo (NCT02184195).
Other genetic drivers
The pancreatic cancer genome showed other focal amplifications of recognised oncogenes. 4 These included ERBB2 (HER2), MET, FGFR1, CDK6, PIK3R3 and PIK3CA, all of which are targets for medications that already exist. While the absolute number of mPDAC patients with each of these genomic aberrances is low, their existence provides a rationale for further studies of individually targeted treatments.
Conclusion
While mPDAC remains a condition with a poor prognosis, there are increasing options for systemic treatment. Beyond these regimens, innovative clinical trials exist for patients who have previously been neglected for the use of targeted treatments. Thus far, targeted agents have had disappointing results in mPDAC, but the majority of trials have been in unselected populations. It is becoming increasingly recognised that sub-groups of mPDAC exist, such as those with microsatellite instability or BRCA mutations, when identified, these can predict for exceptional responses.
Importantly, when considering molecular genomic analysis, this needs to occur as soon as possible after diagnosis. In the trial setting, delays in such investigations have previously negated their benefit, with mPDAC patients often having a limited life expectancy in which to receive and act upon the results. 39, 40 This has been a significant barrier to the translation of this technology into clinical practice in pancreas cancer.
The only way to accelerate progress is through ongoing research and active recruitment of participants to well-designed clinical trials that include translational endpoints. This will require continued strong collaborative efforts between patients and clinicians.
